HRP20160373T1 - Kombinacija antikolinergika i antagonista leukotrien receptora za liječenje bolesti dišnog sustava - Google Patents
Kombinacija antikolinergika i antagonista leukotrien receptora za liječenje bolesti dišnog sustava Download PDFInfo
- Publication number
- HRP20160373T1 HRP20160373T1 HRP20160373TT HRP20160373T HRP20160373T1 HR P20160373 T1 HRP20160373 T1 HR P20160373T1 HR P20160373T T HRP20160373T T HR P20160373TT HR P20160373 T HRP20160373 T HR P20160373T HR P20160373 T1 HRP20160373 T1 HR P20160373T1
- Authority
- HR
- Croatia
- Prior art keywords
- use according
- combination
- physiologically acceptable
- pharmaceutical
- treatment
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims 2
- 239000003199 leukotriene receptor blocking agent Substances 0.000 title claims 2
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 title 1
- 239000000812 cholinergic antagonist Substances 0.000 title 1
- 229940065725 leukotriene receptor antagonists for obstructive airway diseases Drugs 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims 6
- 229940015042 glycopyrrolate Drugs 0.000 claims 5
- 239000008177 pharmaceutical agent Substances 0.000 claims 5
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 4
- 208000006673 asthma Diseases 0.000 claims 4
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 claims 3
- 206010039085 Rhinitis allergic Diseases 0.000 claims 3
- 239000013543 active substance Substances 0.000 claims 3
- 201000010105 allergic rhinitis Diseases 0.000 claims 3
- 208000030603 inherited susceptibility to asthma Diseases 0.000 claims 3
- 229960005127 montelukast Drugs 0.000 claims 3
- 208000023504 respiratory system disease Diseases 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 2
- 201000009240 nasopharyngitis Diseases 0.000 claims 2
- 238000004806 packaging method and process Methods 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 241000282472 Canis lupus familiaris Species 0.000 claims 1
- 241000283086 Equidae Species 0.000 claims 1
- 241000282326 Felis catus Species 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000000414 obstructive effect Effects 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 239000003380 propellant Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Claims (15)
1. Kombinacija R,R-glikopirolata ili njegove fiziološki prihvatljive soli i montelukasta ili njegove fiziološki prihvatljive soli, naznačena time, da se rabi u liječenju respiratornih bolesti, uključujući alergijski rinitis, bronhijalnu astmu, COPD ili prehladu.
2. Kombinacija za uporabu u skladu s patentnim zahtjevom 1, naznačena time, da je dnevna doza inhibitora leukotriena od 1 do 100 mg, poželjno od 5 do 20 mg.
3. Kombinacija za uporabu u skladu s patentnim zahtjevom 1 ili 2, naznačena time, da je dnevna doza R,R-gliko pirolata od 1 do 500 µg.
4. Kombinacija za uporabu u skladu s patentnim zahtjevom 1 ili 2, naznačena time, da je dnevna doza R,R-glikopirolata od 5 do 100 µg.
5. Farmaceutsko sredstvo za uporabu u liječenju respiratornih bolesti, uključujući alergijski rinitis, bronhijalnu astmu, COPD ili prehladu, naznačeno time, da sadržava R,R-glikopirolat ili njegove fiziološki prihvatljive soli i montelukast ili njegove fiziološki prihvatljive soli.
6. Farmaceutsko sredstvo za uporabu u skladu s patentnim zahtjevom 5, naznačeno time, da su aktivne tvari dostupne već pomiješane u određenoj kombinaciji, prema potrebi zajedno s uobičajenim nosačima, pomoćnim tvarima i dodacima, u farmaceutskom obliku prikladnom za inhalacijsku primjenu.
7. Farmaceutsko sredstvo za uporabu u skladu s patentnim zahtjevom 5, naznačeno time, da su dostupne aktivne tvari u zasebnim pakirnim jedinicama, pri čemu se obje supstance mogu uzeti iz zasebnih pakirnih jedinica na takav način, da su na raspolaganju za istovremenu inhalacijsku primjenu.
8. Farmaceutsko sredstvo za uporabu u skladu s patentnim zahtjevom 7,
naznačeno time, da se aktivne tvari mogu primjenjivati nezavisno jedna od druge.
9. Farmaceutsko sredstvo za uporabu u skladu s bilo kojim od patentnih zahtjeva 6 do 8, naznačeno time, da je to inhalacijski aerosol sa ili bez potisnog plina.
10. Farmaceutsko sredstvo za uporabu u skladu s bilo kojim od patentnih zahtjeva 6 do 8, naznačeno time, da je to inhalacijski suhi prah.
11. Farmaceutsko sredstvo za uporabu u skladu s bilo kojim od patentnih zahtjeva 6 do 8, naznačeno time, da je to inhalacijska suspenzija ili otopina.
12. Farmaceutsko sredstvo za uporabu u skladu s bilo kojim od patentnih zahtjeva 6 do 11, naznačeno time, da se nalazi u inhalatoru,
13. Uporaba R,R-glikopirolata ili njegovih fiziološki prihvatljivih soli i montelukasta ili njegovih fiziološki prihvatljivih soli za proizvodnju lijeka za liječenje respiratornih bolesti uključujući alergijski rinitis, bronhijalnu astmu, COPD ili prehladu kod sisavaca.
14. Uporaba u skladu s patentnim zahtjevom 13, naznačena time, da su sisavci mačke, psi, ili konji.
15. Uporaba u skladu s patentnim zahtjevom 13, naznačena time, da su bolesti karakterizirane opstruktivnim komponentama ili uzrokovane upalom poput astme i kronične opstruktivne plućne bolesti (KOPB).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66191805P | 2005-03-16 | 2005-03-16 | |
| PCT/EP2006/002247 WO2006097250A1 (en) | 2005-03-16 | 2006-03-10 | The combination of anticholinergics and leukotriene recptor antagonists for the treatment of repiratory diseases |
| EP06723360.1A EP1863476B1 (en) | 2005-03-16 | 2006-03-10 | The combination of anticholinergics and leukotriene receptor antagonists for the treatment of respiratory diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20160373T1 true HRP20160373T1 (hr) | 2016-05-06 |
Family
ID=36570797
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20160373TT HRP20160373T1 (hr) | 2005-03-16 | 2016-04-12 | Kombinacija antikolinergika i antagonista leukotrien receptora za liječenje bolesti dišnog sustava |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US8268864B2 (hr) |
| EP (1) | EP1863476B1 (hr) |
| JP (1) | JP4991693B2 (hr) |
| CN (1) | CN101128196B (hr) |
| AU (1) | AU2006224842B2 (hr) |
| CA (1) | CA2595791C (hr) |
| CY (1) | CY1117571T1 (hr) |
| DK (1) | DK1863476T3 (hr) |
| ES (1) | ES2570332T3 (hr) |
| HK (1) | HK1114013A1 (hr) |
| HR (1) | HRP20160373T1 (hr) |
| HU (1) | HUE027076T2 (hr) |
| MX (1) | MX2007011273A (hr) |
| NO (1) | NO340405B1 (hr) |
| NZ (1) | NZ560206A (hr) |
| PL (1) | PL1863476T3 (hr) |
| RU (1) | RU2420285C2 (hr) |
| SI (1) | SI1863476T1 (hr) |
| WO (1) | WO2006097250A1 (hr) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050048614A1 (en) * | 2000-06-13 | 2005-03-03 | Children's Medical Center Corporation | Biosynthetic oncolytic molecules and uses therefor |
| KR101149379B1 (ko) * | 2003-07-28 | 2012-06-28 | 얀센 파마슈티카 엔.브이. | 벤즈이미다졸, 벤즈티아졸 및 벤즈옥사졸 유도체 및ｌｔａ4 ｈ 조정자로서의 그의 용도 |
| TW200906396A (en) * | 2007-02-14 | 2009-02-16 | Janssen Pharmaceutica Nv | LTA4H modulators and uses thereof |
| ES2671874T3 (es) | 2007-10-18 | 2018-06-11 | Rose U, Llc | Formulaciones tópicas de glicopirrolato |
| KR20100072295A (ko) * | 2007-10-25 | 2010-06-30 | 머크 프로스트 캐나다 리미티드 | 병용 요법 |
| WO2010144628A2 (en) * | 2009-06-09 | 2010-12-16 | Elevation Pharmaceuticals, Inc. | Treatment of chronic obstructive pulmonary disease with nebulized beta 2-agonist or combined nebulized beta 2-agonist and anticholinergic administration |
| US9378456B2 (en) * | 2012-11-19 | 2016-06-28 | Microsoft Technology Licensing, Llc | Task completion |
| CN105026369A (zh) | 2013-02-28 | 2015-11-04 | 德米拉股份有限公司 | 格隆铵盐 |
| US8558008B2 (en) | 2013-02-28 | 2013-10-15 | Dermira, Inc. | Crystalline glycopyrrolate tosylate |
| US9006462B2 (en) | 2013-02-28 | 2015-04-14 | Dermira, Inc. | Glycopyrrolate salts |
| AU2014249168B2 (en) | 2013-03-12 | 2018-07-12 | Celltaxis, Llc | Methods of inhibiting leukotriene A4 hydrolase |
| MX2015011677A (es) | 2013-03-14 | 2016-07-08 | Celtaxsys Inc | Inhibidores de leucotrieno a4 hidrolasa. |
| RU2685706C2 (ru) * | 2014-01-10 | 2019-04-23 | Эфиммьюн Лимитед | Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением |
| EP3801559A4 (en) | 2018-05-31 | 2022-03-02 | Celltaxis, LLC | METHOD FOR REDUCING LUNG EXACERBATIONS IN PATIENTS SUFFERING FROM RESPIRATORY DISEASE |
| JP2022516729A (ja) * | 2019-01-10 | 2022-03-02 | ジャンイン ムコケア ファーマシューティカル カンパニー，リミテッド | ロイコトリエン受容体アンタゴニストを含有する新たな製剤 |
| EP4099982A1 (en) * | 2020-02-03 | 2022-12-14 | Taro Pharmaceutical Industries Ltd. | Topical montelukast formulations |
| CN115792229A (zh) * | 2022-01-28 | 2023-03-14 | 华中科技大学同济医学院附属同济医院 | 鼻分泌物中tPA在制备鼻息肉及其预后检测剂中的应用 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0435038A (ja) * | 1990-05-31 | 1992-02-05 | Oki Electric Ind Co Ltd | 半導体素子及びその製造方法 |
| EP0706513B1 (de) | 1993-07-02 | 2002-05-15 | Byk Gulden Lomberg Chemische Fabrik GmbH | Fluoralkoxy substituierte benzamide und ihre verwendung als zyklisch-nukleotid phosphodiesterase-inhibitoren |
| EP0932401A1 (en) | 1996-07-01 | 1999-08-04 | Sepracor, Inc. | Methods and compositions for treating urinary incontinence using enantiomerically enriched (r,r)-glycopyrrolate |
| AU745331B2 (en) * | 1996-11-11 | 2002-03-21 | Meda Pharma Gmbh & Co. Kg | Pure enantiomer basic aryl-cycloalkyl-hydroxycarboxylic acid esters, process for preparing the same and their use in medicaments |
| BR9809022A (pt) * | 1997-04-30 | 2000-08-01 | Warner Lambert Co | Composições antiinflamatórias nasais tópicas |
| US6384038B1 (en) * | 1998-04-14 | 2002-05-07 | Sepracor Inc. | Methods and compositions using cetirizine in combination with leukotriene inhibitors or decongestants |
| US6402285B1 (en) * | 1998-05-29 | 2002-06-11 | Citizen Watch Co., Ltd. | Method of subjecting ink jet printer to preuse treatment |
| EP1102579B1 (de) | 1998-08-04 | 2003-03-19 | Jago Research Ag | Medizinische aerosolformulierungen |
| PT1283036E (pt) | 1998-11-13 | 2008-03-06 | Jagotec Ag | Inalador de pó seco de dose múltipla com um reservatório de pó |
| US6086914A (en) * | 1999-03-12 | 2000-07-11 | Weinstein; Robert E. | Nonsedating formulations for allergic rhinitis which possess antihistaminic and anticholinergic activity |
| DE19921693A1 (de) | 1999-05-12 | 2000-11-16 | Boehringer Ingelheim Pharma | Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika |
| US20040002548A1 (en) | 1999-05-12 | 2004-01-01 | Boehringer Ingelheim Pharma Kg | Medicament compositions containing anticholinergically-effective compounds and betamimetics |
| SE9903995D0 (sv) * | 1999-11-03 | 1999-11-03 | Astra Ab | New combination |
| DE19961300A1 (de) | 1999-12-18 | 2001-06-21 | Asta Medica Ag | Vorratssystem für Arzneimittel in Pulverform und damit ausgestatteter Inhalator |
| DE10007203A1 (de) * | 2000-02-17 | 2001-08-23 | Asta Medica Ag | Neue Kombination nichtsedierender Antihistaminika mit Substanzen, die die Leukotrienwirkung beeinflussen, zur Behandlung der Rhinitis/Konjunktivitis |
| GB0008660D0 (en) | 2000-04-07 | 2000-05-31 | Arakis Ltd | The treatment of respiratory diseases |
| GB0009583D0 (en) | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Respiratory formulations |
| EP1335729A2 (de) * | 2000-10-31 | 2003-08-20 | Boehringer Ingelheim Pharma GmbH & Co.KG | Inhalative lösungsformulierung mit einem tiotropiumsalz |
| DE10110772A1 (de) | 2001-03-07 | 2002-09-12 | Boehringer Ingelheim Pharma | Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und PDE-IV-Inhibitoren |
| GB0029903D0 (en) | 2000-12-07 | 2001-01-24 | Arakis Ltd | Use of anti-muscarinic agents |
| ATE375142T1 (de) | 2001-03-30 | 2007-10-15 | Jagotec Ag | Medizinische aerosolformulierungen |
| US6667344B2 (en) | 2001-04-17 | 2003-12-23 | Dey, L.P. | Bronchodilating compositions and methods |
| MXPA03010791A (es) | 2001-05-25 | 2004-03-02 | Boehringer Ingelheim Pharma | Combinacion de inhibidor de pde4 y tiotropio a sus derivados para tratamiento de enfermedades obstructivas de vias respiratorias y de otras enfermedades inflamatorias. |
| JP2005508861A (ja) | 2001-05-25 | 2005-04-07 | ファイザー・インク | 閉塞性気管疾患の治療のためのｐｄｅ４阻害剤及び抗コリン性剤の組み合わせ物 |
| GB0118373D0 (en) | 2001-07-27 | 2001-09-19 | Glaxo Group Ltd | Novel therapeutic method |
| MY148466A (en) * | 2001-10-26 | 2013-04-30 | Merck Frosst Canada Ltd | Granule formulation |
| US7258118B2 (en) | 2002-01-24 | 2007-08-21 | Sofotec Gmbh & Co, Kg | Pharmaceutical powder cartridge, and inhaler equipped with same |
| US20040038958A1 (en) | 2002-07-11 | 2004-02-26 | Chris Rundfeldt | Topical treatment of skin diseases |
| UA82323C2 (uk) | 2002-08-09 | 2008-04-10 | Меда Фарма Гмбх & Ко. Кг | Нова комбінація глюкокортикоїду та pde-інгібітору для лікування респіраторних захворювань, алергічних захворювань, астми та хронічних обструктивних легеневих захворювань |
| WO2004023984A2 (en) * | 2002-09-13 | 2004-03-25 | Smith C Steven | Novel composition and method for treatment of upper respiratory conditions |
| EP1452179A1 (en) * | 2003-02-27 | 2004-09-01 | CHIESI FARMACEUTICI S.p.A. | Novel medicament combination of a highly potent long-lasting beta2-agonist and a corticosteroid |
| ATE384529T1 (de) | 2003-03-28 | 2008-02-15 | Nycomed Gmbh | Synergistische kombination enthaltend roflumilast und einen anticholinergischen wirkstoff ausgewählt aus tiotropiumsalzen für die behandlung von atemwegserkrankungen |
| JPWO2005055999A1 (ja) | 2003-12-08 | 2007-07-05 | 日本新薬株式会社 | 抗コリン作用剤 |
| GB0411056D0 (en) * | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
-
2006
- 2006-03-10 MX MX2007011273A patent/MX2007011273A/es active IP Right Grant
- 2006-03-10 WO PCT/EP2006/002247 patent/WO2006097250A1/en active Application Filing
- 2006-03-10 PL PL06723360T patent/PL1863476T3/pl unknown
- 2006-03-10 DK DK06723360.1T patent/DK1863476T3/en active
- 2006-03-10 JP JP2008501208A patent/JP4991693B2/ja not_active Expired - Fee Related
- 2006-03-10 AU AU2006224842A patent/AU2006224842B2/en not_active Ceased
- 2006-03-10 NZ NZ560206A patent/NZ560206A/en unknown
- 2006-03-10 HU HUE06723360A patent/HUE027076T2/en unknown
- 2006-03-10 CA CA2595791A patent/CA2595791C/en not_active Expired - Fee Related
- 2006-03-10 ES ES06723360T patent/ES2570332T3/es active Active
- 2006-03-10 RU RU2007138270/15A patent/RU2420285C2/ru not_active Application Discontinuation
- 2006-03-10 EP EP06723360.1A patent/EP1863476B1/en active Active
- 2006-03-10 CN CN2006800061530A patent/CN101128196B/zh not_active Expired - Fee Related
- 2006-03-10 SI SI200632036A patent/SI1863476T1/sl unknown
- 2006-03-16 US US11/376,615 patent/US8268864B2/en not_active Expired - Fee Related
-
2007
- 2007-10-16 NO NO20075287A patent/NO340405B1/no not_active IP Right Cessation
-
2008
- 2008-04-14 HK HK08104158.2A patent/HK1114013A1/xx not_active IP Right Cessation
-
2016
- 2016-04-12 HR HRP20160373TT patent/HRP20160373T1/hr unknown
- 2016-04-28 CY CY20161100365T patent/CY1117571T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1863476A1 (en) | 2007-12-12 |
| NO340405B1 (no) | 2017-04-18 |
| WO2006097250A1 (en) | 2006-09-21 |
| EP1863476B1 (en) | 2016-02-03 |
| PL1863476T3 (pl) | 2016-07-29 |
| HUE027076T2 (en) | 2016-08-29 |
| MX2007011273A (es) | 2007-11-08 |
| CA2595791C (en) | 2013-10-08 |
| US20060211729A1 (en) | 2006-09-21 |
| NZ560206A (en) | 2009-09-25 |
| SI1863476T1 (sl) | 2016-05-31 |
| CY1117571T1 (el) | 2017-04-26 |
| DK1863476T3 (en) | 2016-05-17 |
| CN101128196B (zh) | 2013-01-02 |
| CN101128196A (zh) | 2008-02-20 |
| HK1114013A1 (en) | 2008-10-24 |
| RU2420285C2 (ru) | 2011-06-10 |
| US8268864B2 (en) | 2012-09-18 |
| JP2008533072A (ja) | 2008-08-21 |
| AU2006224842B2 (en) | 2011-09-29 |
| CA2595791A1 (en) | 2006-09-21 |
| NO20075287L (no) | 2007-12-05 |
| AU2006224842A1 (en) | 2006-09-21 |
| ES2570332T3 (es) | 2016-05-17 |
| JP4991693B2 (ja) | 2012-08-01 |
| RU2007138270A (ru) | 2009-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20160373T1 (hr) | Kombinacija antikolinergika i antagonista leukotrien receptora za liječenje bolesti dišnog sustava | |
| JP2008533072A5 (hr) | ||
| HRP20200260T1 (hr) | Pripravci, postupci i sustavi za respiratornu isporuku dva ili više aktivnih sredstava | |
| HRP20120286T1 (hr) | Kombinacija antikolinergika i inhibitora fosfodiesteraze tip 4 za liječenje respiratornih bolesti | |
| JP2007520508A5 (hr) | ||
| RU2006132036A (ru) | Комбинация и фармацевтический препарат для лечения аллергий и заболеваний дыхательных путей | |
| JP2007520506A5 (hr) | ||
| HRP20130835T1 (hr) | Farmaceutske formulacije otopine za davanje kao stlaäśeni inhalat u inhalatoru | |
| CY1108978T1 (el) | Συνδυασμος ενωσεων μεθυλξανθινης και στεροειδων για να θεραπευονται χρονιες αναπνευστικες ασθενειες | |
| RU2006132038A (ru) | Комбинация (варианты) и фармацевтический препарат для лечения заболеваний дыхательных путей | |
| JP2010132695A5 (hr) | ||
| CL2009000601A1 (es) | Composicion farmaceutica inhalable en forma de polvo seco que comprende bromuro de aclidinio y un vehiculo, que proporciona una dosis nominal medida de aclinio equivalente a aproximadamente 200 ug de bromuro de aclinio; su uso en epoc y asma; dispositivo inhalador de polvo seco multidosis. | |
| SI2928889T1 (en) | COMPOUNDS WITH ACTIVITY OF ANTAGONIST OF MUSCARIN RECEPTORS AND BETA2 AGENTIST ADRENERGY RECEPTORS | |
| JP2011520911A5 (hr) | ||
| HRP20151214T4 (hr) | Pripravak za inhalaciju koji sadrži aklidinij za liječenje kronične opstruktivne plućne bolesti | |
| BRPI0508170A (pt) | formulações farmacêuticas para inaladores de pó seco, que compreendem um ingrediente ativo de potência de baixa dosagem | |
| JP2019517597A5 (hr) | ||
| BRPI0606283A2 (pt) | formulações de antagonista de receptor de leucotrieno/corticosteróide em nanopartìcula | |
| WO2012085582A1 (en) | Compound | |
| KR20220158030A (ko) | 급성 폐손상 치료용 5-아미노-2,3-디히드로-1,4-프탈라진디온 | |
| BR112014029735A2 (pt) | forma de dosagem e formulação de abediterol | |
| EA201590019A1 (ru) | Ингаляторы сухого порошка, содержащие носитель, отличный от лактозы | |
| ES2610104T3 (es) | Aclidinio para el uso en la mejora de la calidad del sueño en pacientes con enfermedades respiratorias | |
| UY30935A1 (es) | Combinacion:-antagonista del receptor de quimioquina 1 (ccr1) -agonista del receptor de glucocorticoides- opcionalmente agonista b(beta)2, -composicion farmacéutica conteniéndola -aplicaciones. | |
| HRP20160630T1 (hr) | Farmaceutske aerosolne formulacije formoterola i beklometazon-dipropionata |